Alto Neuroscience Q2 net loss widens to $27.64 million; R&D expenses rise to $22.11 million
ANRO•ALTO-207 development timeline
ALTO-207 Phase 2b PACE-1 data is expected in 2H 2027; Phase 3 PACE-2 starts early 2027, and a monotherapy Phase 3 is planned for 2H 2027.
Cash position and July offering
Cash, cash equivalents and restricted cash totaled $244.23 million at June 30; pro forma cash was about $338 million after a July offering.
The July registered direct offering sold 3,776,436 shares at $26.48 for $100 million gross, $94.6 million net, to expand ALTO-207 development.
Q2 loss widens as R&D spending increases
Alto Neuroscience posted a Q2 net loss of $27.64 million; loss per share was $0.65, unchanged from a year earlier.
R&D expense rose 68.43% to $22.11 million; G&A expense increased 26.32% to $7.02 million.
